Litcius/Paper detail

First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

Jianying Lei, Jiahao Zhang, Caicong You, Maobai Liu, Na Li

2024Value in Health11 citationsDOI

Topics & Concepts

MedicineBevacizumabAtezolizumabOncologyCost effectivenessInternal medicineChemotherapyCost-effectiveness analysisCervical cancerQuality-adjusted life yearCancerPembrolizumabImmunotherapyRisk analysis (engineering)Endometrial and Cervical Cancer TreatmentsEconomic and Financial Impacts of CancerHER2/EGFR in Cancer Research
First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis | Litcius